Loading…
Maze Therapeutics, Inc. is projected to rise to $29.97 by 2027, a +11% move from its current price of $26.92. MAZE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $26.24 | $26.92 | $27.62 | -0.01% |
| Aug 3 | $25.96 | $26.92 | $27.91 | -0.01% |
| Aug 4 | $25.74 | $26.91 | $28.14 | -0.02% |
| Aug 5 | $25.57 | $26.91 | $28.33 | -0.03% |
| Aug 6 | $25.41 | $26.91 | $28.50 | -0.04% |
| Aug 7 | $25.27 | $26.91 | $28.65 | -0.04% |
| Aug 8 | $25.14 | $26.91 | $28.80 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.14 | $26.91 | $28.80 | -0.05% |
| Week 2 | $24.43 | $26.89 | $29.60 | -0.10% |
| Week 3 | $23.90 | $26.88 | $30.23 | -0.15% |
| Week 4 | $23.46 | $26.87 | $30.77 | -0.20% |
| Week 5 | $23.07 | $26.85 | $31.25 | -0.25% |
| Week 6 | $22.73 | $26.84 | $31.70 | -0.29% |
| Week 7 | $22.42 | $26.83 | $32.10 | -0.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2.
The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Maze Therapeutics, Inc. trades under the ticker MAZE and is categorized in Healthcare. It currently has a price of $26.92 and a market capitalization of $1.49B, with a market rank of 2149.
The stock sits in a bearish technical environment with near-term support at $25.57 and resistance at $32.84, reflecting a choppy setup around its current level. The current price is positioned near the 2026 forecasted average price, suggesting a flat near-term path before potential longer-term growth.
A major floor 21.3% below — a decisive break under it would weaken the trend.
The nearest floor, 5.0% below — buyers have tended to step in here.
The nearest ceiling, 22.0% above — a clean break opens room to run.
A major ceiling 82.0% above — clearing it would confirm fresh momentum.
Key MAZE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MAZE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.68 | Sell | $27.50 | Sell |
| MA 10 | $27.99 | Sell | $27.92 | Sell |
| MA 20 | $29.19 | Sell | $28.23 | Sell |
| MA 50 | $27.24 | Sell | $28.31 | Sell |
| MA 100 | $29.72 | Sell | $29.76 | Sell |
| MA 200 | $34.57 | Sell | $29.92 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.42 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -99.55 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.35 | Sell |
| ROC (12) | -8.40 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | -0.57 | Sell |
| Ultimate (7,14,28) | 36.99 | Neutral |
| Momentum (10) | -1.20 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 27.21 | Sell |
| ADX (14) | 15.38 | Neutral |
| ATR (14) | 0.74 | Info |
The near-term technical picture remains bearish with RSI(14) at 40. The 50-day simple moving average is at $27.24, while the 200-day moving average sits higher at $34.57. Immediate support is at $25.57 and resistance at $32.84. Over the last 30 days, the price traded between $22.73 and $31.88, indicating a cautious range-bound dynamic as momentum compresses.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $23.58 | $26.92 | $34.39 | 0% | Neutral | |
| $24.03 | $29.97 | $39.43 | +11% | Neutral | |
| $23.66 | $30.29 | $41.30 | +13% | Neutral | |
| $28.45 | $37.23 | $52.19 | +38% | Bullish | |
| $32.57 | $43.44 | $62.32 | +61% | Bullish | |
| $34.79 | $47.22 | $69.14 | +75% | Bullish | |
| $37.94 | $52.32 | $78.03 | +94% | Bullish | |
| $36.12 | $50.57 | $76.67 | +88% | Bullish | |
| $37.45 | $53.20 | $81.89 | +98% | Bullish | |
| $41.81 | $60.20 | $93.99 | +124% | Bullish | |
| $58.06 | $88.95 | $147.34 | +230% | Bullish | |
| $98.89 | $168.36 | $304.07 | +525% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $23.58 | $26.92 | $32.76 | +0.00% |
| September 2026 | $23.28 | $27.49 | $33.35 | +2.12% |
| October 2026 | $22.50 | $26.75 | $32.78 | -2.70% |
| November 2026 | $22.39 | $26.76 | $33.06 | +0.03% |
| December 2026 | $23.02 | $27.63 | $34.39 | +3.27% |
Click any year to see its month-by-month MAZE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Maze Therapeutics, Inc.'s 2026 outlook centres on $26.92, within a $23.58 to $34.39 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, MAZE could reach as high as $39.43, with a base case around $29.97 and support toward $24.03 — roughly +11% from $26.92. A consolidation phase looks the most probable path here.
Expect MAZE to range from $23.66 to $41.30 through 2028. The $30.29 average target implies a +13% move from current prices. That is up +1% on the projected 2027 average. Price action looks broadly range-bound.
The MAZE price prediction for 2029 points to an average of $37.23 (low $28.45, high $52.19) — a potential gain of +38% on today's $26.92. Buyers look set to stay in control over this stretch.
In 2030, MAZE is projected to trade between $32.57 and $62.32, averaging $43.44 — a potential gain of +61% from today's $26.92. That is up +17% on the projected 2029 average. Momentum favours further upside here.
Maze Therapeutics, Inc.'s 2031 outlook centres on $47.22, within a $34.79 to $69.14 range. That is up +9% on the projected 2030 average. That marks a +75% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, MAZE could reach as high as $78.03, with a base case around $52.32 and support toward $37.94 — roughly +94% from $26.92. Momentum favours further upside here.
Expect MAZE to range from $36.12 to $76.67 through 2033. The $50.57 average target implies a +88% move from current prices. That is -3% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The MAZE price prediction for 2034 points to an average of $53.20 (low $37.45, high $81.89) — a potential gain of +98% on today's $26.92. Momentum favours further upside here.
In 2035, MAZE is projected to trade between $41.81 and $93.99, averaging $60.20 — a potential gain of +124% from today's $26.92. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Maze Therapeutics, Inc.'s 2040 outlook centres on $88.95, within a $58.06 to $147.34 range. That is up +48% on the projected 2035 average. That marks a +230% change versus current levels. Momentum favours further upside here.
By 2050, MAZE could reach as high as $304.07, with a base case around $168.36 and support toward $98.89 — roughly +525% from $26.92. Buyers look set to stay in control over this stretch.
Investing $1,000 in MAZE today (≈ 37.147103 MAZE) could be worth
$6,254.16
+$5,254.16 (+525%) by 2050 · US Dollar
Based on the average projected MAZE price of $168.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MAZEwould be worth at today's price.
$1,000 invested in MAZE on Jul 31, 2025 (≈ 67.79661 MAZE) would be worth
$1,825.08
+$825.08 (+82.5%) today · 1.83× · US Dollar
Based on a MAZE entry price of $14.75 vs. today's $26.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.68 | $972.54 | -2.7% |
| 1 month ago | $29.81 | $903.05 | -9.7% |
| 3 months ago | $27.17 | $990.8 | -0.9% |
| 6 months ago | $46.53 | $578.55 | -42.1% |
| 1 year ago | $14.75 | $1,825.08 | +82.5% |
| All time (1.5y) ago | $15.95 | $1,687.77 | +68.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MAZE forecast.
Our base-case forecast reaches $54.00 around 2035.
Implied market cap at $54.00: $2.99B
The multi-year forecast shows a progressive rise in expected value with a bullish tilt from 2029 onward. The 2026 average is $26.92 (min $23.58, max $34.39) with 0% ROI and neutral sentiment. By 2029 the average rises to $37.23 (min $28.45, max $52.19) with 38.3% ROI and bullish momentum.
The 2030 average is $43.44 (min $32.57, max $62.32) with 61.4% ROI and bullish sentiment, followed by continued gains through 2035 (average $60.20, min $41.81, max $93.99; ROI 123.6%) and strong longer-term upside (2040 average $88.95, min $58.06, max $147.34; ROI 230.4%; 2050 average $168.36, min $98.89, max $304.07; ROI 525.4%). The sentiment remains bullish across 2030, 2031, 2032, 2033, 2034, 2035, 2040, and 2050, reflecting a sustained growth trajectory with notable upside potential and substantial long-term risk.
Tap a question to reveal the answer.
2026 forecast: min $23.58, avg $26.92, max $34.39 with ROI 0 and sentiment Neutral.
Forecasts show the price moving from an average of $26.92 in 2026 to higher averages in later years (e.g., $43.44 in 2030 and $168.36 in 2050) with bullish sentiment from 2029 onward and rising ROIs (61.4% in 2030, 230.4% in 2040, 525.4% in 2050). These are estimates, not guarantees, and depend on multiple factors.
The 2030 max is $62.32, and the 2040 max is $147.34, while the 2050 max is $304.07. So, while $100 is not projected for 2030, it is projected to be reached sometime between 2040 and 2050 in the max scenarios.
2026 avg $26.92; 2027 avg $29.97; 2028 avg $30.29; 2029 avg $37.23; 2030 avg $43.44. Each year shows rising averages with bullish momentum beginning in 2029.
Current price is $26.92 and market cap is $1.49B.
Maze Therapeutics, Inc. Community Discussion
0Share your Maze Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.